Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/153771
Full metadata record
DC FieldValueLanguage
dc.creatorPríncipe, C
dc.creatorSousa, IJD
dc.creatorPrazeres, H
dc.creatorSoares, P
dc.creatorLima, RT
dc.date.accessioned2023-11-08T09:57:44Z-
dc.date.available2023-11-08T09:57:44Z-
dc.date.issued2021
dc.identifier.issn1424-8247
dc.identifier.urihttps://hdl.handle.net/10216/153771-
dc.description.abstractLow-density lipoprotein receptor-related protein 1B (LRP1B) is a giant member of the LDLR protein family, which includes several structurally homologous cell surface receptors with a wide range of biological functions from cargo transport to cell signaling. LRP1B is among the most altered genes in human cancer overall. Found frequently inactivated by several genetic and epigenetic mechanisms, it has mostly been regarded as a putative tumor suppressor. Still, limitations in LRP1B studies exist, in particular associated with its huge size. Therefore, LRP1B expression and function in cancer remains to be fully unveiled. This review addresses the current understanding of LRP1B and the studies that shed a light on the LRP1B structure and ligands. It goes further in pre-senting increasing knowledge brought by technical and methodological advances that allow to better manipulate LRP1B expression in cells and to more thoroughly explore its expression and mutation status. New evidence is pushing towards the increased relevance of LRP1B in cancer as a potential target or translational prognosis and response to therapy biomarkers.
dc.description.sponsorshipThis work was funded by FEEI (Fundos Europeus Estruturais e de Investimento), FEDER (Fundo Europeu de Desenvolvimento Regional) funds through the COMPETE2020, Operational Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT (Fundação para a Ciência e a Tecnologia), in the framework of the project: Pre-dicting patient’s response to liposomal anticancer drugs: focusing on LRP1B endocytic activity— PTDC/MEC-ONC/31520/2017. Additionally, it was funded (in part) by Programa Operacional Regional do Norte and co-funded by European Regional Development Fund under the project “The Porto Comprehensive Cancer Center” with the reference NORTE-01-0145-FEDER-072678—Consórcio PORTO.CCC—Porto. Comprehensive Cancer Center.
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC%2FMEC-ONC%2F31520%2F2017/PT
dc.relation.ispartofPharmaceuticals, vol.14(9):836
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBiomarker
dc.subjectCancer
dc.subjectEndocytic receptor
dc.subjectImmune checkpoint inhibitors
dc.subjectLRP1B
dc.subjectPredictor of response
dc.subjectPrognosis
dc.subjectTumor suppressor
dc.titleLrp1b: A giant lost in cancer translation
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/ph14090836
dc.relation.publisherversionhttps://www.mdpi.com/1424-8247/14/9/836
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-ph14090836.pdf3.57 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons